According to recent media publications, the Food and Drug Administration has approved the use of Levemir (insulin detemir) for Type 1 diabetes in children ages 2 to 5 years. According to Novo Nordisk, Levemir, although approved for use in older children and adults for both Type 1 and Type 2 diabetes, is now the first FDA approved basal insulin... Read more
Once again, while listening to National Public Radio, I heard a new category of "jet lag" that is not related to travel. It’s called "social jet lag." Till Roenneberg of The University of Munich seems to have hit upon something quite relevant to nearly all generations--as we all know, there is an incredible amount of research in the... Read more
The New England Journal of Medicine recently published (4/29/12) the results of the TODAY study (Treatment Options for Type 2 Diabetes in Adolescents and Youth). Unfortunately, the results were not encouraging. As everyone is slowly coming to realize, childhood obesity is increasing at an alarming rate. As such, the risk of developing type 2... Read more
Prior to 2001, there were only three basal insulins that were used in combination with either regular or rapid acting insulin. NPH and Lente were intermediate acting insulin (duration 10-12 hours) along with Ultralente (duration 24-36 hours). These basal insulins had peaks that could increase the risk of hypoglycemia. Presently, only NPH is... Read more
We have talked about the "Gold Medalists" of Joslin Clinic--those people with diabetes who lived long lives and passed away from natural causes. The beta cells of those gold medalists were examined, and much to the surprise of all, a small percentage were still producing insulin! This is a very exciting paradigm insofar as that for many years it... Read more
